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Background Results
Complex I (CI) deficiency is a defect of OXPHOS caused by
mutations in the mitochondrial or nuclear genomes. To date
disease-causing mutations have been reported in all
A reduced activity of CI was detected
and BN-PAGE showed a global
expression levels of complex
mitochondrial-encoded subunits and 22 nuclear genes. In about
50% of the patients no mutations are found, suggesting that
undiscovered factors are an important cause of disease.
NDUFB4 (ranging from 75 to 60
amount of the fully assembled complex
(skeletal muscle from) patient II-1
In this study we report a consanguineous family from Southern
Portugal with three affected children presenting with CI deficiency
and 3-methylglutaconic aciduria type IV.
PAGE followed by Western blotting
NDUFS3 monoclonal antibodies
decreased amount of complex I
Patients and Methods
patient II-3 (Fig. 2 C). Due to sample
to perform BN-PAGE for this patient
Patients:
The family presented here is from Southern Portugal (Fig.1). Patient II.1 is the
II-1
NDUFA9
Ctr II-1
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youngest daughter born from healthy consanguineous parents. Her older
siblings (two sisters and one brother) are normal. Patient III.1 is the first son
born to the eldest sister of case II.1. Patient III.2, is sister of patient II.2.
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Figure 2. Complex I assembly and steady-state
(A) SDS-PAGE WB analysis in control (Ctr) and patient
µg of total protein. Specific antibodies, against subunits
Pt 1
II
III
Blue Native- and Sodium Dodecyl Sulfate-PAGE analysis:
II (SDH 70kDa), complex III (Core2), complex IV (COX
mitochondria from muscle of patient II-1 and Ctr. Complex
the CI NDUFA9 (39 kDa) subunit; CIII core2 subunit and
Ctr and patient III-2 skeletal muscle. Loaded samples
against subunits of complex I (NDUFA9, NDUFB4, NDUFS
Pt 2 Pt 3
Figure 1. Pedrigree of the family studied 
For BN-PAGE, mitochondria-enriched fractions were isolated from a 20-100 mg
muscle specimen (Nijtmans et al. 2002). For the (SDS)-PAGE, protein fractions
were prepared either from muscle homogenate or total intact cells.
complex IV (CoxIV) and porin were used.
Western blot:
Protein immunodetection was performed with primary antibodies directed against
several subunits of the mitochondrial complexes. Peroxidase-conjugated anti-
mouse IgG was used as secondary antibody and the signal detected using the
A number of CI associated genes
level however, no mutations were
the three patients excreted highImmobilon Western Chemiluminescent HRP Substrate detection kit (Millipore
Corporation) and the fluorescence were quantified using the software Quantity One
(Bio-Rad).
Molecular analysis:
acid. The presence of 3-methylglutaconic
POLG gene, known to be involved
methylglutaconic aciduria type IVTotal genomic DNA was purified from either blood or muscle using commercially
available kits (EZ1 DNA Blood 350 µl Kit (QIAGEN®); Puregene Tissue kit
(Gentra)). The mitochondrial genes encoding subunits of complex I and the whole
mtDNA were amplified and sequenced using a commercially available kit,
1), that also showed mtDNA depletion,
mutations were found. The mother
whereas the father is carrier of p
mitoSEQr™ Resequencing System for the Human Mitochondrial Genome (Applied
Biosystems), according to the procedure recommended by the manufacturer.
Several nuclear genes that encodes subunits of complex I, as well as assembly
factors were amplified by PCR, purified with Exo-SAP (GE Healthcare, USA), and
no POLG mutations were found.
directly sequenced using the BigDye1.1 chemistry on an ABI Prism 3130 Genetic
Analizer (Applied Biosystems, Foster City, CA).
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Discussion
Molecular diagnosis of patients with complex I deficiency is a
challenging task not only due to the clinical heterogeneity of the
patients but also due to the large number of candidate genes
in two of the patients. SDS
reduction of the protein
I subunits NDUFA9, NDUFB8,
(both nuclear and mitochondrial encoded). Besides all the
advances in molecular technology it is known that a number of
% reduction) and a decreased
I (approximately 30%) in
(Fig. 2 A and B). Through SDS- cases remain unsolved (Calvo et al., 2010, Tucker et al., 2011).
The molecular basis of complex I deficiency in this family is still
not completely elucidated. It remains unanswered whether this
using NDUFA9, NDUFB4 and
it was also possible to observe a
subunits in skeletal muscle from
family, due to the high consanguinity, could have two different
disorders (“double trouble”) or if an yet unknown gene leading to
complex I deficiency could be involved. Patient II.1 carries two
limitation it was not possible
.
mutations in the POLG gene however none of the other patients
carries any of the mutations. Due to its function, it is tempting toNDUFA9
III-2 CtrCtr
C
speculate that variations in POLG might contribute or modulate
the clinical and biochemical phenotype, or both. Under this
assumption, POLG will impair mtDNA replication, affecting the
SDH70
NDUFB4
synthesis of ND subunits. This ultimately could affect the ND
subunits pools, that are believed to exist, and consequently affect
complex I assembly due to its dependence on ND subunits to
NDUFS3
CV-alfa
CoxIV
form the membrane arm (Ugalde, 2004). Additionally the three
patients present 3-methylglutaconic aciduria type IV, which
comprise a very heterogeneous group both in presentation as in
Porin
molecular etiologies, that adds up to the riddle in this family. The
advances in technology available such as exome sequencing will
levels of mitochondrial proteins
II-1 skeletal muscle. Loaded samples correspond to 30
of complex I (NDUFA9, NDUFB8, NDUFB4), complex
certainly shed light for the molecular basis of CI deficiency and 3
methylglutaconic aciduria in this family.
II) and porin were used. (B) BN-PAGE WB analysis of
I was immunovisualized using antibodies against
CIV, COXII subunit. (C) SDS-PAGE WB analysis in
correspond to 30 µg of total protein. Specific antibodies,
3), complex II (SDH 70kDa), complex III (Core2),
Table 1. Summary of the clinical and laboratory findings
Clinical, Histological and CI residual 
mtDNA Nuclear genes SDS-PAGE
were investigated at molecular
detected. Besides CI deficiency
amounts of 3-methylglutaconic
Patient Age Biochemical Data activity
II.1 4m Psychomotor delay, hypotonia
which evolved to spasticity,
neurosensorial deafness and
epilepsy. Urinary organic acids
37% ND1-ND6, ND4L: 
negative
NDUFS2,8; 
NDUFV1-2; 
NDUFAF1,2,4: 
negative 
NDUFA9, 
NDUFB8, 
NDUFB4: 
decreased
acid prompt us to study
in the etiology of 3-
. In only one of the patients (II-
showed presence of 3-
methylglutaconic acid (208
µmol/mmol creatinine). Increased
levels of plasma and CSF lactate
and pyruvate. Morphology –
predominance of type I fibers.
the p.G848S/p.Q1236H
of II-1 is carrier of p.Q1236H
.G848S. In patients III-1 and III-2
Deceased at 10 months
III.1 1m Nephew of patient II-1.
Hypotonia, nystagmus and
feeding difficulties. Urinary
organic acids showed the
presence of 3-methylglutaconic
Not done Not done Not done Not done
acid. Increased levels of plasma
and CSF lactate and pyruvate.
Deceased at 2 months. Muscle
biopsy not performed
III.2 1m Sister of patient III-1. Similar 38% ND1-ND6, ND4L: NDUFS1,2,4: NDUFA9, 
clinical phenotype of previous
cases. Urinary organic acids
showed the presence of 3-
methylglutaconic acid (1363
µmol/mmol creatinine). Deceased
at 12 months
negative negative NDUFB4, 
NDUFS3: 
decreased
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